Study of CellCept for Advanced Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00997958|
Recruitment Status : Completed
First Posted : October 20, 2009
Last Update Posted : April 25, 2014
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: Mycophenolate mofetil||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of CellCept for Advanced Pancreatic Cancer|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||January 2009|
Administered in tablet form twice daily one hour after eating.
Drug: Mycophenolate mofetil
Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.
Each patient will be treated for eight weeks (56 days).
- Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997958
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Robert L Fine, MD||Columbia University|